Pancreatic cancer is a deadly disease with high mortality due to difficulties in its early
diagnosis and metastasis. The tumor microenvironment induced by interactions between …

Pancreatic ductal adenocarcinoma (PDAC) has a dismal prognosis, with a median survival
time of 10-12 months. Clinically, these poor outcomes are attributed to several factors …

Pancreatic ductal adenocarcinoma (PDA) is notoriously aggressive and hard to treat. The
tumour microenvironment (TME) in PDA is highly dynamic and has been found to promote …

The preclinical drug screening of pancreatic cancer treatments suffers from the absence of
appropriate models capable to reproduce in vitro the heterogeneous tumor …

Pancreatic cancer is one of the most lethal malignancies worldwide. Although the standard
of care in pancreatic cancer has improved, prognoses for patients remain poor with a 5-year …

Heparanase is the only mammalian enzyme that cleaves heparan sulphate, an important
component of the extracellular matrix. This leads to the remodelling of the extracellular …

Pancreatic stellate cells (PSCs) were identified in the early 1980s, but received much
attention after 1998 when the methods to isolate and culture them from murine and human …

Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal human malignancies
with a 5-year survival rate of 8%. Dense, fibrotic stroma associated with pancreatic tumors is …

Background Pancreatic cancer (PC) is among foremost causes of cancer related deaths
worldwide due to generic symptoms, lack of effective screening strategies and resistance to …

Pancreatic adenocarcinoma (PDAC) is a fatal disease with a 5-year survival rate of 8% and
a median survival of 6 mo. In PDAC, several mutations in the genes are involved, with …